PL377344A1 - Lekarstwo do profilaktyki i leczenia miażdżycy tętnic i nadciśnienia - Google Patents

Lekarstwo do profilaktyki i leczenia miażdżycy tętnic i nadciśnienia

Info

Publication number
PL377344A1
PL377344A1 PL377344A PL37734404A PL377344A1 PL 377344 A1 PL377344 A1 PL 377344A1 PL 377344 A PL377344 A PL 377344A PL 37734404 A PL37734404 A PL 37734404A PL 377344 A1 PL377344 A1 PL 377344A1
Authority
PL
Poland
Prior art keywords
arteriosclerosis
hypertension
medicine
prevention
treatment
Prior art date
Application number
PL377344A
Other languages
English (en)
Inventor
Masatsugu Horiuchi
Masaru Iwai
Toshio Sada
Makoto Mizuno
Original Assignee
Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32828917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL377344(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sankyo Company, Limited filed Critical Sankyo Company, Limited
Publication of PL377344A1 publication Critical patent/PL377344A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL377344A 2003-01-31 2004-01-29 Lekarstwo do profilaktyki i leczenia miażdżycy tętnic i nadciśnienia PL377344A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003022990 2003-01-31
JP2003030830 2003-02-07

Publications (1)

Publication Number Publication Date
PL377344A1 true PL377344A1 (pl) 2006-01-23

Family

ID=32828917

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377344A PL377344A1 (pl) 2003-01-31 2004-01-29 Lekarstwo do profilaktyki i leczenia miażdżycy tętnic i nadciśnienia

Country Status (20)

Country Link
US (6) US20060009502A1 (pl)
EP (2) EP1604664A4 (pl)
JP (2) JP3874419B2 (pl)
KR (2) KR101194453B1 (pl)
AU (1) AU2004208615C1 (pl)
BR (1) BRPI0406987A (pl)
CA (1) CA2514921C (pl)
CR (1) CR7928A (pl)
EA (1) EA009983B1 (pl)
EC (1) ECSP055935A (pl)
HR (1) HRP20050754A2 (pl)
IL (1) IL169719A (pl)
IS (1) IS7985A (pl)
ME (1) ME00479B (pl)
MX (1) MXPA05008142A (pl)
NZ (1) NZ541454A (pl)
PL (1) PL377344A1 (pl)
RS (1) RS20050590A (pl)
TW (1) TWI373335B (pl)
WO (1) WO2004067003A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006131511A (ja) * 2004-11-02 2006-05-25 Japan Health Science Foundation 虚血性脳障害抑制剤
KR101429484B1 (ko) * 2005-04-12 2014-08-13 바이코어 파마 아베 신규한 트리시클릭 안지오텐신 ⅱ 아고니스트
EP1869024B1 (en) * 2005-04-12 2010-11-10 Vicore Pharma AB New tricyclic angiotensin ii agonists
JP5000491B2 (ja) * 2005-05-20 2012-08-15 第一三共株式会社 フィルムコーティング製剤
KR101314439B1 (ko) * 2005-05-20 2013-10-07 다이이찌 산쿄 가부시키가이샤 덱스트로오스 함유 필름 코팅 제제
TWI405580B (zh) * 2005-06-27 2013-08-21 Sankyo Co 含有血管收縮素ｉｉ接受器拮抗劑及鈣通道阻斷劑之醫藥調配物
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
TW200736245A (en) * 2005-11-29 2007-10-01 Sankyo Co Acid addition salts of optically active dihydropyridine derivatives
TW200806648A (en) 2005-11-29 2008-02-01 Sankyo Co Acid addition salts of dihydropyridine derivatives
KR101422052B1 (ko) * 2006-04-19 2014-07-23 아지노모토 가부시키가이샤 할선 정제
EP1891952B1 (en) 2006-05-04 2011-10-05 LEK Pharmaceuticals d.d. Pharmaceutical composition of olmesartan medoxomil
BRPI0713371A2 (pt) * 2006-06-27 2012-03-13 Daiichi Sankyo Company, Limited método para a produção de um produto medicamentoso contendo olmesartan medoxomil, e, produto medicamentoso contendo olmesartan medoxomil
TWI399223B (zh) 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
KR101247583B1 (ko) * 2006-12-08 2013-03-26 한미사이언스 주식회사 암로디핀 또는 이의 약제학적 허용가능한 염, 및 로자탄또는 이의 약제학적 허용가능한 염을 함유하는 약제학적조성물
TW200833325A (en) * 2006-12-26 2008-08-16 Daiichi Sankyo Co Ltd Pharmaceutical composition comprising ascorbic acid
TWI414310B (zh) * 2006-12-26 2013-11-11 Daiichi Sankyo Co Ltd 溶出性改善之醫藥品組成物
TWI402083B (zh) * 2006-12-26 2013-07-21 Daiichi Sankyo Co Ltd 固形製劑及其安定化方法
TWI488658B (zh) * 2006-12-26 2015-06-21 Daiichi Sankyo Co Ltd 溶出性之改善方法
JP2008290989A (ja) * 2007-05-28 2008-12-04 Ube Ind Ltd ジヒドロピリジン誘導体の酸付加塩を含有する医薬
US8133924B2 (en) * 2007-08-13 2012-03-13 Rhodia Operations Demulsifiers and methods for use in pharmaceutical applications
ES2510866T3 (es) 2008-03-13 2014-10-21 Daiichi Sankyo Company, Limited Mejora de la solubilidad de una preparación que contiene olmesartán medoxomilo
WO2010076596A1 (en) * 2008-12-30 2010-07-08 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical formulations of olmesartan
JP6081058B2 (ja) * 2009-03-19 2017-02-15 第一三共株式会社 包装により安定保存された固形製剤
IT1400311B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
AU2020278825A1 (en) 2019-05-21 2021-10-21 Société des Produits Nestlé S.A. Entre-deux-Villes 1800 Vevey Switzerland Dietary butyrate

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
US4573909A (en) * 1984-08-03 1986-03-04 Granco-Clark, Inc. Billet heating furnace with adjustable pressurized entrance seal
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US4772596A (en) 1986-10-09 1988-09-20 Sankyo Company Limited Dihydropyridine derivatives, their preparation and their use
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
FR2681067B1 (fr) 1991-09-10 1993-12-17 Elf Sanofi Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
US5250521A (en) * 1990-12-07 1993-10-05 Merck & Co., Inc. Substituted pyrazolopyrimidines as angiotensin II antagonists
US5260285A (en) * 1990-12-07 1993-11-09 Merck & Co., Inc. Substituted imidazopyridazines as angiotensin II antagonists
CA2057089A1 (en) 1990-12-07 1992-06-08 Eric E. Allen Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin ii antagonists
JP3398379B2 (ja) 1990-12-14 2003-04-21 スミスクライン・ビーチャム・コーポレイション アンジオテンシンｉｉ受容体遮断組成物
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
CA2229000C (en) 1991-02-21 2002-04-09 Sankyo Company, Limited 1-biphenylimidazole derivatives, their preparation and their therapeutic use
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
EP0502575A1 (en) 1991-03-06 1992-09-09 Merck & Co. Inc. Substituted 1-(2H)-isoquinolinones
US5238942A (en) * 1991-05-10 1993-08-24 Merck & Co., Inc. Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists
US5492904A (en) * 1991-05-15 1996-02-20 E. I. Du Pont De Nemours And Company Composition of angiotensin-II receptor antagonists and calcium channel blockers
NZ242724A (en) * 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
US5246944A (en) * 1991-08-13 1993-09-21 Merck & Co., Inc. Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
CA2079982A1 (en) 1991-10-07 1993-04-08 Stephen E. De Laszlo Substituted pyrazino (2,3-d)-pyrimidinones as angiotensin ii antagonists
FR2688781B1 (fr) * 1992-03-23 1994-07-01 Sanofi Elf Imidazolines n-substituees par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
JP2750331B2 (ja) * 1992-04-23 1998-05-13 株式会社ジャパンエナジー エピタキシャル成長用基板およびエピタキシャル成長方法
US5312820A (en) * 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
US5343167A (en) * 1993-02-03 1994-08-30 Silicon Systems, Inc. One-shot control circuit for tracking a voltage-controlled oscillator
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
JP3057471B2 (ja) * 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
GB9405833D0 (en) * 1994-03-24 1994-05-11 Pfizer Ltd Separation of the enantiomers of amlodipine
US6251436B1 (en) * 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US6036977A (en) * 1995-09-29 2000-03-14 L.A.M. Pharmaceutical Corp. Drug preparations for treating sexual dysfunction
US5952006A (en) * 1995-09-29 1999-09-14 L.A.M. Pharmaceuticals, Llc Drug preparations for treating impotency
US5808084A (en) * 1996-02-14 1998-09-15 Pfizer, Inc. Process for the preparation of 1,4-dihydropyridinedicarboxylic esters
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
CN1214682A (zh) 1996-03-29 1999-04-21 史密丝克莱恩比彻姆公司 Eprosartan二水合物及其制备和制剂方法
US6420412B2 (en) * 1996-03-29 2002-07-16 Smithkline Beecham Corporation Eprosartan dihydate and a process for its production and formulation
CZ299162B6 (cs) * 1996-07-15 2008-05-07 Sankyo Company, Limited Farmaceutický prípravek a souprava
US5879303A (en) * 1996-09-27 1999-03-09 Atl Ultrasound Ultrasonic diagnostic imaging of response frequency differing from transmit frequency
DE69807695T2 (de) * 1997-06-27 2003-07-31 Smithkline Beecham Corp., Philadelphia Eprosartan-monohydrate
ES2273433T3 (es) 1997-08-06 2007-05-01 Smithkline Beecham Corporation Complejo por neutralizacion de cargas con arginilo de eprosartan y procedimiento para su produccion y formulacion.
US6630498B2 (en) * 1997-08-06 2003-10-07 Smithkline Beecham Corporation Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
JP4880118B2 (ja) 1997-11-17 2012-02-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 薬物高充填性の即時放出性または放出を修飾した経口用投与処方およびその製法
ZA991922B (en) 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
US20030022928A1 (en) * 1998-03-11 2003-01-30 Smithkline Beecham Corporation Novel compositions of eprosartan
DE69927154T2 (de) 1998-06-25 2006-06-29 Lavipharm Laboratories, Inc. Vorrichtung und verfahren zur behandlung von erektionsstörungen
US20020127254A1 (en) * 1998-06-25 2002-09-12 Lavipharm Laboratories Inc. Devices for local and systemic delivery of active substance and methods of manufacturing thereof
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
AU1042199A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Antihypertensive medicaments containing lacidipine and telmisartan
WO2000027396A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Medicaments based on combinations of lacidipine and telmisartan or of physiological derivatives thereof
WO2000047617A1 (en) * 1999-02-09 2000-08-17 Lexicon Genetics Incorporated Human uncoupling proteins and polynucleotides encoding the same
US6395728B2 (en) * 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
WO2001005428A1 (fr) * 1999-07-21 2001-01-25 Takeda Chemical Industries, Ltd. Methodes preventives contre la recurrence d'une insuffisance cerebrovasculaire, et agents destines a ameliorer des troubles causes par une insuffisance cerebrovasculaire et a inhiber leur evolution
CZ300687B6 (cs) 1999-08-30 2009-07-15 Sanofi - Aventis Deutschland GmbH Léciva s obsahem ramiprilu k ošetrování kardiovaskulárních príhod
US6521647B2 (en) * 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
GB0008332D0 (en) 2000-04-04 2000-05-24 Pfizer Ltd Treament
GB2361185A (en) * 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
DE60119715T3 (de) 2000-04-10 2016-12-08 Nicholas John Wald Zusammensetzung zur prävention kardiovaskulärer erkrankungen
JP4327376B2 (ja) * 2000-04-11 2009-09-09 第一三共株式会社 カルシウムブロッカーを含有する安定化された薬剤組成物
HUP0300444A3 (en) * 2000-04-11 2007-09-28 Sankyo Co Stabilized pharmaceutical compositions containing calcium channel blockers
DE10018401A1 (de) 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
WO2002017913A1 (fr) * 2000-08-30 2002-03-07 Sankyo Company, Limited Compositions medicinales utilisees dans la prevention ou le traitement de l'insuffisance cardiaque
PT1336407E (pt) * 2000-11-21 2006-07-31 Sankyo Co Composicao contendo um antagonista do receptor de angiotensina e um diuretico e sua utilizacao para o tratamento da hipertensao
US20040087484A1 (en) * 2000-12-01 2004-05-06 Sahota Pritam Singh Combination of organic compounds
US20030138494A1 (en) * 2001-05-15 2003-07-24 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
EP1413315A4 (en) * 2001-08-03 2006-08-16 Takeda Pharmaceutical DRUGS WITH CONTINUOUS RELEASE
US6680334B2 (en) * 2001-08-28 2004-01-20 Pfizer Inc Crystalline material
HUP0401696A2 (hu) * 2001-08-28 2004-11-29 Sankyo Co., Ltd. Angiotenzin-II receptor antagonistát tartalmazó gyógyászati készítmény
JP2005508358A (ja) * 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
JP5100039B2 (ja) * 2003-01-31 2012-12-19 第一三共株式会社 動脈硬化及び高血圧症の予防及び治療のための医薬
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
US20050209588A1 (en) * 2003-09-04 2005-09-22 Crum, Kaminski & Larson, Llc HIFU resculpturing and remodeling of heart valves
US20050187262A1 (en) * 2004-01-12 2005-08-25 Grogan Donna R. Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
TWI405580B (zh) * 2005-06-27 2013-08-21 Sankyo Co 含有血管收縮素ｉｉ接受器拮抗劑及鈣通道阻斷劑之醫藥調配物

Also Published As

Publication number Publication date
NZ541454A (en) 2008-04-30
CR7928A (es) 2007-10-03
US20080176910A1 (en) 2008-07-24
EA009983B1 (ru) 2008-04-28
EP3045174A1 (en) 2016-07-20
AU2004208615C1 (en) 2010-05-13
US20060252806A1 (en) 2006-11-09
EP1604664A1 (en) 2005-12-14
JP3874419B2 (ja) 2007-01-31
KR20050094884A (ko) 2005-09-28
AU2004208615A1 (en) 2004-08-12
JP2010189426A (ja) 2010-09-02
TWI373335B (en) 2012-10-01
US20080214626A1 (en) 2008-09-04
JP5190086B2 (ja) 2013-04-24
CA2514921A1 (en) 2004-08-12
EP1604664A4 (en) 2006-12-27
ECSP055935A (es) 2006-04-19
MXPA05008142A (es) 2005-09-30
US20060252805A1 (en) 2006-11-09
BRPI0406987A (pt) 2006-01-10
CA2514921C (en) 2013-04-30
US20060009502A1 (en) 2006-01-12
KR20120058618A (ko) 2012-06-07
TW200510389A (en) 2005-03-16
US20080176909A1 (en) 2008-07-24
WO2004067003A1 (ja) 2004-08-12
JPWO2004067003A1 (ja) 2006-05-18
HRP20050754A2 (en) 2005-10-31
RS20050590A (en) 2007-09-21
IS7985A (is) 2005-08-17
ME00479B (me) 2011-10-10
EA200501075A1 (ru) 2006-02-24
IL169719A (en) 2011-07-31
KR101194453B1 (ko) 2012-10-24

Similar Documents

Publication Publication Date Title
EP1604664A4 (en) MEDICAMENT FOR THE PREVENTION AND TREATMENT OF ARTERIOSCLEROSIS AND BLOOD HIGH PRESSURE
AU2004208615B2 (en) Medicine for prevention of and treatment for arteriosclerosis and hypertension
AU2003290548A8 (en) Prevention and treatment of synucleinopathic disease
HK1190084A1 (zh) 用於預防和治療補體相關紊亂的 多肽
SI2075000T1 (sl) Kombinacija azelastina in ciklezonida
IL180517A0 (en) Novel statin pharmaceutical compositions and related methods of treatment
TWI347188B (en) Treatment and prevention of osteoporosis
HK1108168A1 (en) Vaccine for prevention and treatment of hiv-infection
SI1487541T1 (sl) Uporaba inhibitorjev il-18 za zdravljenje in /alipreventivo bolezni perifernega oĺ˝ilja
ZA200600733B (en) Treatment and prevention of cardiovascular events
IL174577A0 (en) Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
HUP0303306A3 (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases
EP1551456A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING RENAL DISEASES
PT1680405E (pt) Derivados de bengamida e sua utilização para o tratamento de doenças cancerosas
ZA200701916B (en) Novel statin pharmaceutical compositions and related methods of treatment
IL166083A0 (en) Methods for treatment and prevention of gastrointestinal conditions
NO20054020D0 (no) Medisin for forhindring og behandling av arterosklerose og hypertensjon
AU2003245674A8 (en) Oral disease prevention and treatment
AU2003227257A1 (en) Medicine for prevention and/or therapy of cardiomyopathy
GB0304021D0 (en) Treatment of hypertension
IL151658A0 (en) Methods and compositions for the treatment or prevention of cardiovascular diseases
GB0329357D0 (en) Treatment of materials
HK1119248A1 (en) Screening and treatment methods for prevention of preterm delivery
SI1610785T1 (sl) Farmacevtski kombiniran pripravek za zdravljenje spastiäśnosti in/ali boleäśine